摘要
目的 :观察内皮素受体拮抗剂PD14 50 65联合内皮源血管松驰因子NO生理性前体L -arginine对大鼠缺血性急性肾衰竭是否有防治作用。方法 :采用阻断大鼠双侧肾脏血流 4 5min再灌注 2 4h之急性肾缺血再灌注动物模型 ,观察内皮素受体拮抗剂PD14 50 65或内皮源血管松驰因子NO生理性前体L -arginine或两者联合应用 ,对再灌注2 4h后大鼠肾组织病理变化和肾功能的影响。结果 :PD14 50 65或L -arginine单独作用均可明显减轻肾缺血再灌注后的肾组织病理损害 ,提高肾小球滤过率 ,改善肾功能。其中 ,两者联合应用的效果比单独使用的效果更好。结论 :缺血性急性肾衰竭时 ,内皮素升高及其受体上调是缺血性急性肾衰竭发生发展的重要因素 ,外源性给予内皮素受体拮抗剂可阻断内皮素的生物作用 ,并且联合内皮源血管松弛因子的应用效果更佳。这是防治缺血性急性肾衰竭的又一新途径。
Objective:To investigate PD 145065, an endothelin receptor antagonist (ETRA) and L-Arginine,a donor of endothelium derived relaxing factor(EDRF) in preventing ischemic acute renal failure (IARF).Methods:Acute renal ischemic/reperfusion animal model of bilateral nephrectomy in rats were employed. PD 145065 and L-arginine alone or in combination were injected for 24 hours. Renal histology and renal function were examined.Results:Renal histology and function were significantly improved by PD 145065 and L-arginine alone or in combination. PD 145065 combined with L-arginine was better than PD 145065 or L-arginine alone.Conclusion:Exogenic endothelium receptor antagonist can block the biological effect of endothelium, and shows better effect when combining with endothelium derived relaxing factor. We believe that endothelium receptor antagonist may be a new way to prevent and treat ischemic renal failure.
出处
《中国中西医结合肾病杂志》
2004年第3期133-135,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
广东省医学科研基金资助项目 (No .A1998479)
